HHS unveiled a broad effort to speed up and modernize early-stage clinical trials, aiming to cut development timelines by six to 12 months. The push includes a pilot program focused on the existing Investigational New Drug (IND) pathway. Federal health officials linked the work to a goal of encouraging more U.S.-based trial execution and addressing China’s momentum in early development. The plan is tied to the president’s 2027 fiscal budget proposal to establish a more permanent faster pathway. The move comes as the biotech and pharma industry has urged regulators to reduce bottlenecks that slow trial readiness and downstream data generation.